Diltiazem 1 is an orally and intravenously active calcium channel blocking agent shown to
be an effective and well-tolerated treatment for stable angina and angina due to coronary …

Objective Recent guidelines by the National Institute for Health and Clinical Excellence
(NICE) and the American College of Cardiology/American Heart Association/European …

Background: It has been assumed that cardioversion in patients with atrial fibrillation lasting
less than 48 hours is associated with a low risk for thromboembolism. However, no clinical …

We evaluated the efficacy and the safety of medium-(240 mn/day) and high-dose (360
mg/day) diltiazem alone and in combination with digoxin when used for control of heart rate …

This study evaluates the effectiveness and safety of intravenous diltiazem for the treatment of
atrial fibrillation and atrial flutter. A double-blind, parallel, randomized, placebo-controlled …

Although digpxin is often the first choice for control of ventricular response in chronic atrial
fibrillation, it fails to slow exercise rates. Diltiazem, a calcium channel antagonist that slows …

The clinical relevance and high social costs of atrial fibrillation have boosted interest in rate
control as a cost-effective alternative to long-term maintenance of sinus rhythm (ie rhythm …

To evaluate the influence of calcium entry blockade (diltiazem 60 mg qid) on exercise
capacity in patients with chronic atrial fibrillation, nine men (mean age 65 years) with atrial …

Fourteen patients (four females) with chronic atrial fibrillation were entered into a
randomized, double-blind crossover study to compare the effects of treatment with diltiazem …

Calcium channel blockers depress atrioventricular (AV) nodal properties in vivo in a
frequency-dependent manner, suggesting that selective drug action during supraventricular …